
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an extraction completion and analyst views. COMPASS REPORTS EARNINGS: On Tuesday,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ENVB | Enveric Biosciences | 1.39 | -4.20 | -75.13% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.39 | -75.13% |

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an extraction completion and analyst views. COMPASS REPORTS EARNINGS: On Tuesday,

Enveric Biosciences (ENVB) announced results from a quantitative electroencephalography, qEEG, study of its lead candidate, EB-003, in mice. The study demonstrated modulation of brain activity in prefrontal and parietal regions

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a production completion, a supply agreement and process validation OPTIMI COMPLETES MDMA

Enveric Biosciences (ENVB) announced positive results from recently completed IND-enabling in vitro Absorption, Distribution, Metabolism, Excretion and Toxicity, ADMET, studies for its lead non-hallucinogenic, neuroplastogenic candidate EB-003. The comprehensive in

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, initiation plans and an enrollment update. DEFINIUM’S PHASE 3 PANORAMA

Enveric Biosciences (ENVB) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office, USPTO, for a patent application covering novel compounds within its

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, analyst notes and a notice of allowance. EARNINGS: On Monday, Bright

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a DSMB approval and a CEO appointment. EARNINGS: On Thursday, GH

Enveric Biosciences (ENVB) announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003. Preclinical testing of EB-003 was conducted

Enveric Biosciences (ENVB) welcomed the U.S. Food and Drug Administration’s recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. “The final guidance reflects the FDA’s continued
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $6.31M | ― | ― | 0.00 | -0.23 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.